The neurological diseases treatment market is observed as the most diversified and competitive market comprising large number of players globally. The key driving factors assisting the growth of these two segments are rising prevalence of neurological diseases, incessant development in diagnostic technology, and rising awareness associated with early disease diagnosis through awareness campaigns carried out by governmental or non-governmental organizations. However, market entry of efficient drugs in the near future due to presence of strong drug pipeline is expected to impact the market share of traditional drug treatments and further boost the overall growth of this market. Rising research and development activities in the field of neurology has been the key driver for neurological diseases treatment market and is expected to fuel its growth throughout the forecast period (2023 – 2030). The neurological diseases treatment market is expected to grow at a CAGR of 5.1% during the forecast period 2023-2030.
Anticholinergic and Antiepileptic Segment Led the Market revenues in 2021
The anticholinergic and antiepileptic segment alone contribute to over 44% of the revenue share in 2021. This is largely due to increased focus on R&D in these drugs segment and its application in controlling muscle movement. Increasing prevalence of neurological disorders remains as the key driver to market growth.
Treatment for Alzheimer’s Top the Market Revenues
Based on therapeutic segment, Alzheimer’s disease dominated the market segment in 2021. Intense R&D initiatives are the key reason for the largest share of Alzheimer’s segment, apart from other drivers such as increasing prevalence rate across the globe. Alzheimer’s is also expected to retain its top positon throughout the forecast period. Parkinson’s disease remains as the second largest market for neurological treatment drugs market.
APAC to Grow the Fastest
After scrutiny of the neurological diseases treatment market, regional trends, market sizes, and the overall growth paired with the latest and anticipated events, Asia Pacific is observed to be the most attractive region for the neurological diseases treatment market owing to a swift growth in the uptake of medicines to prevent surging disabilities, death and to improvise on quality of living.
Drug Approvals and Pipelines Remain the Key Focus Area Among the Top Players
It is evident that drug related activities are the most preferred strategy among the top players. Drug related activities include drug approval across various geographies, presenting clinical trial outcomes, receiving permission to launch neurology drugs in various phases of clinical trials. Strategies such as mergers and acquisitions and partnerships & collaborations are comparatively insignificant in this market. Other strategies include receiving recognitions, creating awareness, participation in neurology related events and so on. The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis, GSK, Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc among others.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Neurological Diseases Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2022-2032 |
Base Year | 2023 |
Forecast Period | 2024-2032 |
Historical Year | 2022 |
Unit | USD Million |
Segmentation | |
Drugs
| |
Therapeutic
| |
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report